<DOC>
	<DOCNO>NCT01393990</DOCNO>
	<brief_summary>The objective study determine safe dose LY2228820 may give patient advanced cancer . Part A study consist dose escalation , Part B consist dose confirmation .</brief_summary>
	<brief_title>A Study LY2228820 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer ( include lymphoma ) advance metastatic disease therapy high priority ( approved therapy therapy publish substantial evidence effectiveness ) available , standard therapy exists Have presence measurable nonmeasurable disease define Modified Response Evaluation Criteria Solid Tumors ( RECIST ) Have adequate hematologic , renal , hepatic organ function Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , investigational therapy least 14 day ( 42 day mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy Males females reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug . Females child bear potential must negative serum pregnancy test less equal 7 day prior first dose study drug . Have estimate life expectancy great equal 12 week Are able swallow capsule and/or tablet Have receive treatment within 14 day initial dose study drug drug receive regulatory approval indication Have history major surgical resection involve stomach small bowel , serious preexist medical condition ( base judgment investigator ) Have symptomatic central nervous system malignancy metastasis ( screen require ) Have diagnosis inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Have active hematologic malignancy lymphoma Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) . Screening baseline require enrollment Concurrent administration immunosuppressive therapy Females pregnant lactate Have receive , within 7 day initial dose study drug , either grapefruit juice treatment drug know inhibitor inducer Cytochrome P450 Enzyme 3A4 ( CYP3A4 ) . In addition , patient receive grapefruit juice treatment CYP3A4 inhibitor inducer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>